fig5

Figure 5. (A) Schematic illustration of the injectable hydrogel and its role in T cell recruitment, reversal of T cell exhaustion, and MHC I-regulated immune escape in cancer immunotherapy; (B) In vivo inhibitory effects of the hydrogel on primary tumor and abscopal tumors. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001 [reproduced with permission from Zhang et al. (2022)^[150]. Copyright 2022 John Wiley and Sons]. MHC I: Major histocompatibility complex class I.